Merbarone: an antitumor agent entering clinical trials Alice GloverHoo G. ChunBrian Leyland-Jones Preclinical Review Pages: 137 - 143
Comparison of cancer chemotherapeutic agents in asynchronous and synchronous 9L cells Sheri D. HendersonBrace F. KimlerMary L. Barnes Preclinical Studies Pages: 145 - 154
The colony inhibition of a new chemotherapeutic agent (KW2152) against human lung cancer cell lines James R. JettNagahiro SaijoMasaaki Tesada Preclinical Studies Pages: 155 - 159
The PIT method: an automated in vitro technique for drug toxicity testing Rob van LambalgenPeter Lelieveld Preclinical Studies Pages: 161 - 165
New application of a stabilized active cyclophosphamide derivative (Mafosfamide, ASTA Z 7654) — immunogenic properties of lymphatic leukemia L 1210 cells treated in vitro with the drug Tomasz SkórskiMaciej Kawalec Preclinical Studies Pages: 167 - 169
Phase I and pharmacokinetic study of high volume intraperitoneal aclacinomycin — A (Aclarubicin) Ian G. KerrSherry ArcherJohn McKee Phase I and Pharmacology Trials Pages: 171 - 176
Phase I trial and pharmacokinetic study of intravenous and oral α-Difluoromethylornithine Constance A. GriffinMilan SlavikMartin D. Abeloff Phase I and Pharmacology Trials Pages: 177 - 186
Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors Charles L. VogelElizabeth GorowskiNiramol Savaraj Phase I and Pharmacology Trials Pages: 187 - 198
Mitoxantrone in the treatment of advanced non-squamous carcinoma of the cervix (A phase II trial of the gynecologic oncology group) Hyman B. MussBrian N. BundyGeorge Wilbanks Phase II Trials Pages: 199 - 202
Phase II trial of N-methylformamide in advanced head and neck cancer Walter C. VogelArlene A ForastiereGary Schnur Phase II Trials Pages: 203 - 206
Pulmonary toxicity associated with fludarabine monophosphate Paul G. HurstMichael P. HabibBernard R. Greenberg Case Report Pages: 207 - 210